$GILD Headlines Speculators should retain a flexible

New Post Public Reply Private Reply Replies (0) Message Board

Dec 6, 2013 at 11:31 AM

$GILD Headlines

Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt

Wall Street Breakfast: Must-Know News 6:33 a.m. Today - Seeking Alpha
Leukemia drugs in focus at hematology meeting 4:34 a.m. Today - Seeking Alpha
4 Potential Blockbuster Drugs Awaiting Launch 5:21 p.m. Dec. 5, 2013 - Investors Business Daily
Are Biotech ETFs Back on Track? - ETF News And Commentary 12:04 p.m. Dec. 4, 2013 - Zacks.com
Update on Gilead's Legal Troubles - Analyst Blog 11:40 a.m. Dec. 4, 2013 - Zacks.com
Biotech Stock Predictions 2014: Vertex is Bought, Alexion Sinks, BlueBird Flies And More 11:35 a.m. Dec. 4, 2013 - TheStreet.com
Biotech Stock Roundup: CBST Hits 52-Week High, OREX Lights Up - Analyst Blog 10:59 a.m. Dec. 4, 2013 - Zacks.com
Time to Reconsider Sector Weights 10:00 a.m. Dec. 4, 2013 - RealMoney.com
Best Biotech CEO of 2013: Your Vote Counts 8:07 a.m. Dec. 4, 2013 - TheStreet.com
Medidata, CaesarStone Among New Buys Of Top Funds 5:41 p.m. Dec. 3, 2013 - Investors Business Daily
Chipotle, Cognizant: Stocks That Frank Caruso Likes 5:41 p.m. Dec. 3, 2013 - Investors Business Daily
Gilead Sciences Inc (GILD): Today's Featured Health Care Laggard 5:03 p.m. Dec. 3, 2013 - TheStreet.com
Limited impact on Gilead expected from Idenix lawsuit: Wells 11:40 a.m. Dec. 2, 2013 - Seeking Alpha
Idenix initiates Phase 2 HCV trial, files patent infringement suits against Gilead 8:38 a.m. Dec. 2, 2013 - Seeking Alpha
Weekly Top Insider Sells: GOOG, FCX, GILD, P, OCN 8:22 a.m. Dec. 2, 2013 - GuruFocus.com
Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences 6:08 a.m. Dec. 2, 2013 - benzinga.com
3 Invesco Funds Delivering Great Returns (revised) - Analyst Blog 11:50 a.m. Nov. 29, 2013 - Zacks.com
UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns 10:16 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
Healthcare coverage initiations roundup 8:55 a.m. Nov. 27, 2013 - Seeking Alpha

Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 5:00 p.m. Dec. 2, 2013 - BusinessWire
Critical Alerts For General Electric, Gilead Sciences, Morgan Stanley, Qualcomm, and Adobe Released By InvestorsObserver 9:31 a.m. Dec. 2, 2013 - PR Newswire
Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics 8:40 a.m. Dec. 2, 2013 - PR Newswire
Gilead Sciences, Inc. Uses the PHT Corporation LogPad(R) System for 1st Antianginal Drug to Treat Type 2 Diabetes 8:00 a.m. Dec. 2, 2013 - BusinessWire
Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences 7:00 a.m. Dec. 2, 2013 - GlobeNewswire
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel Lucent SA 9:47 a.m. Nov. 27, 2013 - ACCESSWIRE
Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare 8:00 a.m. Nov. 27, 2013 - PR Newswire
Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife 8:00 a.m. Nov. 25, 2013 - PR Newswire
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Consumer365 Lauds Happy Head's Custom Hair Treatments

Revolutionizing Hair Loss Treatment The world of hair growth solutions is transforming right before our eyes. Thanks to the folks over at Happy Head and their customizable, dermatologist-prescribed treatments, the days of one-size-fits-all are ending. Consumer365 recently took a dive into Happy Head's model, giving their nod of approval to its personalized approach....

Rho Adds Credit Card Payments to Invoices

Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...

Hims & Hers Faces Lawsuit as FTC Alleges Privacy Breach

FTC Cracks Down on Hims & Hers Privacy Practices Most folks don't wake up wanting to find their investments tangled in legal drama. But here we are with Hims & Hers Health (NYSE: HIMS), facing fire from the Federal Trade Commission (FTC). They’re being called out for allegedly spilling the beans on users' sensitive health data—something they claimed to keep under...

China Hour Expands Chinese Media Footprint in Africa

An Ambitious Cross-Continental Media Play The airwaves are getting a new twist. This time, it's a blend of cultures, as China Hour makes an entrance in South Africa. That's right, folks—Jiangsu Broadcasting Corporation (JSBC) has set up camp alongside the South African Broadcasting Corporation (SABC), pushing a big media wave across the continent. If you've been...

Actinium Pharma Unveils Plans at Key Investor Conference

Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...

Auto Maintenance: Key Tips for Long-Term Vehicle Health

Beating Breakdown Blues: Preventative Maintenance Insights You ever look under the hood and wonder what's ticking away? Cars ain't just about turning keys and hitting gas—there's a beating heart under all that metal and rubber. That's what HelloNation's serving us here, with David Mantz and his kid, David Mantz Jr., lifting the lid on preventative maintenance. These...

Patented Foodservice Firm's $1.6M Sale: High ROI Potential

Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...

Papa John's Faces Securities Class Action Over Missteps

Papa John's Stock Takes a Nosedive Here's a hot potato for you—Papa John's International, Inc. (NASDAQ: PZZA) just got slapped with a securities class action. This ain't a pie you want a slice of, not after the dough they lost in a day's trading frenzy. On August 6, our friends at Papa John's sent their investors scrambling as their stock tumbled from $29.75 to a stark...

Testing Grounds: Navigating PRN Test Insights

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Hyundai's Revolutionary US Steel Mill Set for 2029 Rollout

Hyundai's Major Steel Move: A Multibillion-Dollar Stake The steel industry scene in the U.S. just got a lot hotter with Hyundai's announcement of a $5.8 billion Electric Arc Furnace-based integrated steel mill in Louisiana. This game-changing project isn’t just a headline; it’s a concrete step towards beefing up the U.S. manufacturing backbone. Talk about...